Page 3 - Orchid Pharma
NCLT reads insolvency rules at Orchid Pharma's promoter group firm
The bank's dues, by July 2018, were Rs 215.7 crore
 "NCLT reads insolvency rules at Orchid Pharma's promoter group firm")
Resolution professional for insolvent Orchid Pharma to invite new EoI
The NCLT issued its order after Ingen failed to deposit Rs 1,000 cr for the creditors
 "Resolution professional for insolvent Orchid Pharma to invite new EoI")
Orchid Pharma RP hits roadblock as Ingen Capital fails to infuse funds
While the NCLT on Nov 2 has sought Ingen Capital to pay Rs 3.34 billion by Orchid Pharma - in 5 days, the investor has not infused any fund during that time
 "Orchid Pharma RP hits roadblock as Ingen Capital fails to infuse funds")
Big haircut for lenders as NCLT okays resolution plan for Orchid Pharma
The National Company Law Tribunal (NCLT), Chennai Bench has approved the resolution plan submitted by US-based investor Ingen Capital Group LLC for Chennai-based pharmaceutical manufacturer Orchid Pharma Ltd, following which the management will be consituted under the control of the new investor. The lenders may take a haircut and would receive around Rs 10 billion out of the total Rs 32 billion outstanding, according to sources close to the development. The company today informed the exchanges that the resolution plan by Ingen Capital Group has been approved by the NCLT on September 17 under the Insolvency and Bankruptcy Code, 2016.Ingen has to pay the amount in 30 days and has to settle the banks by the time. A consortium of 24 banks has lend a total of over Rs 32 billion to the pharmaceutical manufacturer in the past, apart from the amount due to the employees and other outstanding payments. "The Banks will have to take a haircut and may be able to recover Rs 10 billion out of the .
Orchid Pharma shares go up 5% on rumours about prospective buyers
There were reports that Aurobindo Pharma and Dr Reddy's, are looking at buying the company, which is under Corporate Insolvency Resolution Process
Orchid Pharma net loss widens
Total income from operations stood at Rs 190.91 crore during this quarter, as against Rs 256.33 crore comparing to same quarter past year
 "Orchid Pharma net loss widens")
Orchid Pharma rises on EIR report from USFDA for Alathur facility
The company said it has received EIR from USFDA for its Alathur facility
 "Orchid Pharma rises on EIR report from USFDA for Alathur facility")
